HES1: A Potential Drug Target and Biomarker (G3280)

Target Name: HES1

NCBI ID: G3280

HES1

HES1: A Potential Drug Target and Biomarker

Hairy-like protein (HES1) is a protein that has been identified in various organisms as a potential drug target and biomarker. HES1 is a cytoplasmic protein that is expressed in most eukaryotic cells and is involved in various cellular processes such as cell signaling, cell adhesion, and cytoskeletal organization.

The discovery of HES1 as a potential drug target comes from a study by the research group of Dr. Yoshiko Sueda at the University of California, San Diego. The study identified that HES1 was highly expressed in various human cancer tissues and was associated with cancer progression. The researchers also found that inhibiting HES1 reduced the growth of cancer cells in cell culture and animal models.

Furthermore, HES1 has also been identified as a potential biomarker for cancer diagnosis and treatment. The researchers found that HES1 was expressed in various human tissues, including cancer tissues, and was associated with the severity of cancer. They also found that HES1 was downregulated in cancer tissues, which could be used as a potential biomarker for cancer diagnosis and treatment.

In addition to its potential drug target and biomarker properties, HES1 has also been shown to play a role in various cellular processes. HES1 is involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. It is also involved in the regulation of cell signaling, which is the process by which cells communicate with each other to coordinate their actions.

HES1 has also been shown to be involved in the regulation of cytoskeletal organization, which is the process by which cells organize their cytoskeletons to maintain their shape and stability. This is important for various cellular processes, including cell movement and the regulation of cell division.

The potential drug target and biomarker properties of HES1 make it an attractive candidate for further research. Further studies are being conducted to determine the full extent of HES1's involvement in various cellular processes and to explore its potential as a drug target and biomarker.

In conclusion, HES1 is a protein that has been identified in various organisms as a potential drug target and biomarker. Its potential drug target and biomarker properties make it an attractive candidate for further research. Further studies are being conducted to determine the full extent of HES1's involvement in various cellular processes and to explore its potential as a drug target and biomarker.

Protein Name: Hes Family BHLH Transcription Factor 1

Functions: Transcriptional repressor of genes that require a bHLH protein for their transcription. May act as a negative regulator of myogenesis by inhibiting the functions of MYOD1 and ASH1. Binds DNA on N-box motifs: 5'-CACNAG-3' with high affinity and on E-box motifs: 5'-CANNTG-3' with low affinity (By similarity). May play a role in a functional FA core complex response to DNA cross-link damage, being required for the stability and nuclear localization of FA core complex proteins, as well as for FANCD2 monoubiquitination in response to DNA damage

The "HES1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HES1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets